CYP3A4 and cancer: The present finding that the expression and oxidative activity of CYP3A4 is markedly increased by dinaciclib will be important for the formulation of optimal dosage regimens in clinical cancer therapy (Figure 5B), since CYP3A4 metabolizes approximately 60% of therapeutic drugs and its inhibition frequently causes unfavorable DDIs and toxicity [64].